Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LDHA | P00338 | 1/20 | 0.38 |
| ▸ | SRR | Q9GZT4 | 1/20 | 0.38 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.32 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.32 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.32 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.32 |
| ▸ | MME | P08473 | 1/20 | 0.31 |
| ▸ | ACE | P12821 | 1/20 | 0.31 |
| ▸ | CPA1 | P15085 | 1/20 | 0.31 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL355795 | 1.00 | LDHA (0.38) | LDHASRRFFAR3CYP2C9HDAC3 | |
| SCHEMBL30532234 | 0.88 | TSHR (0.33) | TSHR | |
| SCHEMBL10777977 | 0.81 | HDAC1 (0.41) | LDHASRRFFAR3HDAC3HDAC1 | |
| SCHEMBL29411100 | 0.78 | GAA (0.41) | LMNAEGLN1 | |
| SCHEMBL10780876 | 0.78 | CA2 (0.42) | ACE2TSHR | |
| SCHEMBL29199347 | 0.77 | LDHA (0.40) | LDHASRRCYP2C9TSHRLMNA | |
| SCHEMBL10031543 | 0.76 | — | — | |
| SCHEMBL16445585 | 0.74 | GPR84 (0.48) | ACE2TSHR | |
| SCHEMBL2021291 | 0.74 | USP2 (0.44) | LDHASRRFFAR3HDAC3HDAC1 | |
| SCHEMBL3838841 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026105133-A1 | TNF- Α AND IL-17 INHIBITOR COMPOUNDS FOR THE TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | DAMLE LATHA (IN) | 2026-05-21 | — | — | WO | claimed |
| US-10724008-B2 | Ketoreductases | C-LECTA GMBH (DE) | 2020-07-28 | — | — | US | claimed |
| WO-2020026143-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA (CH) | 2020-02-06 | — | — | WO | claimed |
| US-20200040108-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | PROCTER & GAMBLE INTERNATIONAL OPERATIONS SA | 2020-02-06 | — | — | US | claimed |
| EP-3604346-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | Procter & Gamble International Operations SA (CH) | 2020-02-05 | — | — | EP | claimed |
| US-10093905-B2 | Ketoreductases | C-LECTA GMBH (DE) | 2018-10-09 | — | — | US | claimed |
| EP-3134519-B1 | KETOREDUCTASES | C LECTA GMBH (DE) | 2018-06-06 | — | — | EP | claimed |
| US-20170218345-A1 | KETOREDUCTASES | C-LECTA GMBH (DE) | 2017-08-03 | — | — | US | claimed |
| EP-3134519-A1 | KETOREDUCTASES | c-LEcta GmbH (DE) | 2017-03-01 | — | — | EP | claimed |
| EP-2569275-B1 | A PROCESS FOR THE HYDROGENATION OF KETOESTERS | LONZA AG (CH) | 2016-01-27 | — | — | EP | claimed |
| US-20070243594-A1 | Oxidoreductase from Pichia Capsulata | IEP GMBH (DE) | 2007-10-18 | — | — | US | claimed |
| US-20070173660-A1 | Catalytic composition and process for asymmetric hydrogenation | PHOENIX CHEMICALS LIMITED (GB) | 2007-07-26 | — | — | US | claimed |
| CN-1839153-A | Oxidoreductase from pichia capsulata | IEP GMBH (DE) | 2006-09-27 | — | — | CN | claimed |
| WO-2006091470-A2 | IMPROVED HALOHYDRIN DEHALOGENASES AND RELATED POLYNUCLEOTIDES | CODEXIS, INC. (US) | 2006-08-31 | — | — | WO | claimed |
| US-7056540-B2 | Enzymatic process for the preparation of optically active alcohols from ketones using tuberous root Daucus carota | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2006-06-06 | — | — | US | claimed |
| US-20060099700-A1 | Enzymatic polypeptide comprising halogenase activity for use in production of 4-substituted-3-butyric acid derivatives and vicinal cyano, hydroxyl substituted carboxylic acid esters; bioremediation; pollution control | INNOVATUS LIFE SCIENCES LENDING FUND I, LP, AS COLLATERAL AGENT | 2006-05-11 | — | — | US | claimed |
| EP-1628762-A1 | CATALYTIC COMPOSITION AND PROCESS FOR ASYMMETRIC HYDROGENATION | Phoenix Chemicals Limited (GB) | 2006-03-01 | — | — | EP | claimed |
| WO-2004103560-A1 | CATALYTIC COMPOSITION AND PROCESS FOR ASYMMETRIC HYDROGENATION | PHOENIX CHEMICALS LIMITED (GB) | 2004-12-02 | — | — | WO | claimed |
| US-20040082043-A1 | Enzymatic process for the preparation of optically active alcohols from ketones using tuberous root daucus carota | COUNCIL OF SCIENTIFIC AND INDUSTRIAL RESEARCH (IN) | 2004-04-29 | — | — | US | claimed |
| US-6218157-B1 | EFFICIENT METHOD BY REACTING A 4-HALOACETOACETIC ACID ESTER WITH PURIFIED ENZYME TO FORM (S)-4-HALO-3-HYDROXYBUTYRIC ACID ESTER | DAICEL CHEMICAL INDUSTRIES, LTD. (JP) | 2001-04-17 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070173660-A1 | Catalytic composition and process for asymmetric hydrogenation | KHK, HK2, HK1 | LDHA 153/4885SRR 584/4885FFAR3 3131/4885 |
| US-20060099700-A1 | Enzymatic polypeptide comprising halogenase activity for use in production of 4-substituted-3-butyric acid derivatives and vicinal cyano, hydroxyl substituted carboxylic acid esters; bioremediation; pollution control | HDHD5, HPD, CPB1 | LDHA 418/4885SRR 1208/4885FFAR3 1136/4885 |
| US-20200040108-A1 | PROCESS FOR MAKING A CONSUMER PRODUCT COMPRISING MODIFIED POLYSACCHARIDES | MGAM, FUT5, FUT6 | LDHA 1504/4885SRR 278/4885FFAR3 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.